Adam Bress, PharmD, MS

Research Interests

  • Health Disparities
  • Pharmacoepidemiology
  • Pharmacogenetics
  • Cardiovascular Disease Prevention and Treatment
  • Hypertension
  • Heart Failure


  • English

Academic Information

  • Departments: Population Health Sciences - Assistant Professor
  • Divisions: Health System Innovation and Research

Academic Office Information

  • Williams Building
    295 Chipeta Way
    Salt Lake City, UT 84108

Academic Bio

Dr. Bress is an Assistant Professor of Population Health Sciences in the Division of Health System Innovation and Research and an Investigator at the VA Salt Lake City Health Care System.

Dr. Bress received his Doctor of Pharmacy degree from the University of Maryland, and his Masters of Science in Clinical and Translational Science from the University of Illinois at Chicago School of Public Health with a focus on epidemiology. He completed his residency in pharmacy practice at Yale-New Haven Hospital and Cardiology at the University of Illinois at Chicago. He subsequently completed his post-doctoral research fellowship in cardiovascular pharmacogenomics at the University of Illinois at Chicago.

Dr. Bress is a formally-trained cardiovascular clinical pharmacist and population scientist. His research is focused on the prevention and treatment of cardiovascular disease, optimizing medication use, and reducing health disparities. He is particularly interested in studying antihypertensive medication use to help patients, providers, health systems, and population health managers make better decisions about to how to treat and control high blood pressure. He is also interested in genetic ancestry and racial/ethnic differences in antihypertensive medication responses.

Dr. Bress's research is currently NIH-funded as Principal Investigator by a K01 (K01HL133468) and R01 (R01HL139837) from the NHLBI. He is also PI of an NHLBI R13 Conference grant (R13HL144012) to support the University of Utah Translational Hypertension Symposium. Dr. Bress's research has been published as first author in the New England Journal of Medicine, The Journal of the American College of Cardiology, and Circulation and has been covered in TIME Magazine, The New York Times, and CBS radio.

Dr. Bress has established collaborations with a multi-disciplinary team of investigators in hypertension, cardiology, health services research, epidemiology, and pharmacogenetics at the University of Utah and around the country. He is an active member of the hypertension working groups for two ongoing NIH-funded cohort studies including the Jackson Heart Study (JHS) and the Coronary Artery Risk Development in Young Adults (CARDIA) Study. He is also an active member of the Systolic Blood Pressure Intervention Trial (SPRINT) Research Group.

Dr. Bress has received peer-reviewed extramural research support as Principal Investigator (PI) from the National Institutes of Health (NIH) specifically from the National Heart, Lung, and Blood Institute (NHLBI). He is currently PI of a five-year K01 award which is determining the association between genetic ancestry, including individual genetic variants, with blood pressure control, antihypertensive medication responses, and cardiovascular disease outcomes in African Americans. This project will identify genetic factors that may account for observed racial differences in antihypertensive medication response, potentially identify new approaches for optimizing antihypertensive medication prescribing and thereby improve blood pressure control rates in African Americans. His mentors and scientific advisors for this award are Lynn Jorde (human genetics), Rachel Hess (health services research), Rick Kittles (genetic ancestry and health disparities), Donna Arnett (pharmacogenetics), Paul Muntner (hypertension epidemiology), and Tom Greene (biostatistics).

He also received grant support from the biomedical industry as PI for investigator-initiated research projects focused on cardiovascular pharmacoepidemiology.

Research Statement

I am a cardiovascular clinical pharmacist with training in epidemiology and pharmacogenetics. We focus on disparities in prevention and treatment of cardiovascular disease with a focus on hypertension and antihypertensive medication use. Using pharmacoepidemiology and pharmacogenetics, we try to better understand causes of racial differences in medication responses and outcomes. We apply these findings to understand the population-level impact, generalizability, and cost-effectiveness in diverse groups.

Education History

Type School Degree
Research Fellow University of Illinois at Chicago
Cardiovascular Pharmacogenomics
Research Fellow
Graduate Training University of Illinois at Chicago School of Public Health
Clinical and Translational Science
Residency University of Illinois at Chicago
Residency Yale-New Haven Hospital
Pharmacy Practice
Doctoral Training University of Maryland

Global Impact


Description Country
Speaker. What to Start? Constructing the First Line ART Regimen in Malawi. St. Gabriel’s Hospital, Namitete, Malawi Malawi
Speaker. Strategies to Improve Adherence to Antiretroviral Therapy. St. Gabriel’s Hospital, Namitete, Malawi Malawi
Featured Faculty, "Optimizing antihypertensive treatment in 2017: Lessons using pharmacoepidemiology and pharmacoeconomics", China Heart Congress, Beijing, China, August 10th, 2017 China

Selected Publications

Journal Article

  1. LaFleur J, Bress AP, Esker S, Knippenberg K, Crook J, Nyman H, Bedimo R, Tebas P, Rosenblatt L (2018). Brief Report: Tenofovir-Associated Nephrotoxicity Among a US National Historical Cohort of HIV-Infected Veterans: Risk Modification by Concomitant Antiretrovirals. J Acquir Immune Defic Syndr, 77(3), 325-330.
  2. Still CH, Rodriguez CJ, Wright JT Jr, Craven TE, Bress AP, Chertow GM, Whelton PK, Whittle JC, Freedman BI, Johnson KC, Foy CG, He J, Kostis JB, Lash JP, Pedley CF, Pisoni R, Powell JR, Wall BM (2017). Clinical Outcomes by Race and Ethnicity in the Systolic Blood Pressure Intervention Trial (SPRINT): A Randomized Clinical Trial. Am J Hypertens, 31(1), 97-107.
  3. Butler MJ, Tanner RM, Muntner P, Shimbo D, Bress AP, Shallcross AJ, Sims M, Ogedegbe G, Spruill TM (2017). Adherence to antihypertensive medications and associations with blood pressure among African Americans with hypertension in the Jackson Heart Study. J Am Soc Hypertens, 11(9), 581-588.e5.
  4. King JB, Azadani PN, Suksaranjit P, Bress AP, Witt DM, Han FT, Chelu MG, Silver MA, Biskupiak J, Wilson BD, Morris AK, Kholmovski EG, Marrouche N (2017). Left Atrial Fibrosis and Risk of Cerebrovascular and Cardiovascular Events in Patients With Atrial Fibrillation. J Am Coll Cardiol, 70(11), 1311-1321.
  5. Bress AP, Bellows BK, King JB, Hess R, Beddhu S, Zhang Z, Berlowitz DR, Conroy MB, Fine L, Oparil S, Morisky DE, Kazis LE, Ruiz-Negron N, Powell J, Tamariz L, Whittle J, Wright JT Jr, Supiano MA, Cheung AK, Weintraub WS, Moran AE (2017). Cost-Effectiveness of Intensive versus Standard Blood-Pressure Control. N Engl J Med, 377(8), 745-755.
  6. Bress AP, King JB, Kreider KE, Beddhu S, Simmons DL, Cheung AK, Zhang Y, Doumas M, Nord J, Sweeney ME, Taylor AA, Herring C, Kostis WJ, Powell J, Rastogi A, Roumie CL, Wiggers A, Williams JS, Yunis R, Zias A, Evans GW, Greene T, Rocco MV, Cushman WC, Reboussin DM, Feinglos MN, Papademetriou V (2017). Effect of Intensive Versus Standard Blood Pressure Treatment According to Baseline Prediabetes Status: A Post Hoc Analysis of a Randomized Trial.LID - dc170885 [pii]LID - 10.2337/dc17-0885 [doi]. (Epub ahead of print) Diabetes Care.
  7. LaFleur J, Bress AP, Rosenblatt L, Crook J, Sax PE, Myers J, Ritchings C (2017). Cardiovascular outcomes among HIV-infected veterans receiving atazanavir. AIDS, 31(15), 2095-2106.
  8. Booth JN 3rd, Abdalla M, Tanner RM, Diaz KM, Bromfield SG, Tajeu GS, Correa A, Sims M, Ogedegbe G, Bress AP, Spruill TM, Shimbo D, Muntner P (2017). Cardiovascular Health and Incident Hypertension in Blacks: JHS (The Jackson Heart Study). Hypertension, 70(2), 285-292.
  9. Shallcross AJ, Butler M, Tanner RM, Bress AP, Muntner P, Shimbo D, Ogedegbe G, Sims M, Spruill TM (2017). Psychosocial correlates of apparent treatment-resistant hypertension in the Jackson Heart Study. J Hum Hypertens, 31(7), 474-478.
  10. King JB, Shah RU, Sainski-Nguyen A, Biskupiak J, Munger MA, Bress AP (2017). Effect of Inpatient Dobutamine versus Milrinone on Out-of-Hospital Mortality in Patients with Acute Decompensated Heart Failure. Pharmacotherapy, 37(6), 662-672.
  11. Bress AP, Colantonio LD, Booth JN 3rd, Spruill TM, Ravenell J, Butler M, Shallcross AJ, Seals SR, Reynolds K, Ogedegbe G, Shimbo D, Muntner P (2017). Modifiable Risk Factors Versus Age on Developing High Predicted Cardiovascular Disease Risk in Blacks.LID - e005054 [pii]LID - 10.1161/JAHA.116.005054 [doi]. J Am Heart Assoc, 6(2).
  12. Bress AP, Kramer H, Khatib R, Beddhu S, Cheung AK, Hess R, Bansal VK, Cao G, Yee J, Moran AE, Durazo-Arvizu R, Muntner P, Cooper RS (2017). Potential Deaths Averted and Serious Adverse Events Incurred From Adoption of the SPRINT (Systolic Blood Pressure Intervention Trial) Intensive Blood Pressure Regimen in the United States: Projections From NHANES (National Health and Nutrition Examination Survey). Circulation, 135(17), 1617-1628.
  13. Kansal MM, Mansour IN, Ismail S, Bress A, Wu G, Mirza O, Marpadga R, Gheith H, Kim Y, Li Y, Cavallari L, Stamos TD (2017). Left ventricular global longitudinal strain predicts mortality and heart failure admissions in African American patients. Clin Cardiol, 40(5), 314-321.
  14. Ravenell J, Shimbo D, Booth JN 3rd, Sarpong DF, Agyemang C, Beatty Moody DL, Abdalla M, Spruill TM, Shallcross AJ, Bress AP, Muntner P, Ogedegbe G (2017). Thresholds for Ambulatory Blood Pressure Among African Americans in the Jackson Heart Study. Circulation, 135(25), 2470-2480.
  15. Bress AP, Tanner RM, Hess R, Gidding SS, Colantonio LD, Shimbo D, Muntner P (2016). Prevalence of Eligibility Criteria for the Systolic Blood Pressure Intervention Trial in US Adults Among Excluded Groups: Age <50 Years, Diabetes Mellitus, or a History of Stroke.LID - 10.1161/JAHA.116.003547 [doi]LID - e003547 [pii]. J Am Heart Assoc, 5(7).
  16. Tajeu GS, Kent ST, Kronish IM, Huang L, Krousel-Wood M, Bress AP, Shimbo D, Muntner P (2016). Trends in Antihypertensive Medication Discontinuation and Low Adherence Among Medicare Beneficiaries Initiating Treatment From 2007 to 2012. Hypertension, 68(3), 565-75.
  17. Stone RH, Bress AP, Nutescu EA, Shapiro NL (2016). Upper-Extremity Deep-Vein Thrombosis: A Retrospective Cohort Evaluation of Thrombotic Risk Factors at a University Teaching Hospital Antithrombosis Clinic. Ann Pharmacother, 50(8), 637-44.
  18. Brixner D, Biltaji E, Bress A, Unni S, Ye X, Mamiya T, Ashcraft K, Biskupiak J (2016). The effect of pharmacogenetic profiling with a clinical decision support tool on healthcare resource utilization and estimated costs in the elderly exposed to polypharmacy. J Med Econ, 19(3), 213-28.
  19. Bress AP, Tanner RM, Hess R, Colantonio LD, Shimbo D, Muntner P (2016). Generalizability of SPRINT Results to the U.S. Adult Population. J Am Coll Cardiol, 67(5), 463-72.
  20. Mansour IN, Bress AP, Groo V, Ismail S, Wu G, Patel SR, Duarte JD, Kittles RA, Stamos TD, Cavallari LH (2016). Circulating Procollagen Type III N-Terminal Peptide and Mortality Risk in African Americans With Heart Failure. J Card Fail, 22(9), 692-9.
  21. Bress AP, King JB, Brixner D, Kielhorn A, Patel HK, Maya J, Lee VC, Biskupiak J, Munger M (2016). Pharmacotherapy Treatment Patterns, Outcomes, and Health Resource Utilization Among Patients with Heart Failure with Reduced Ejection Fraction at a U.S. Academic Medical Center. Pharmacotherapy, 36(2), 174-86.
  22. King JB, Shah RU, Bress AP, Nelson RE, Bellows BK (2016). Cost-Effectiveness of Sacubitril-Valsartan Combination Therapy Compared With Enalapril for the Treatment of Heart Failure With Reduced Ejection Fraction. JACC Heart Fail, 4(5), 392-402.
  23. Bress A, Kittles R, Wing C, Hooker SE Jr, King A (2015). Genetic ancestry as an effect modifier of naltrexone in smoking cessation among African Americans: an analysis of a randomized controlled trial. Pharmacogenet Genomics, 25(6), 305-12.
  24. Sharabiani A, Bress A, Douzali E, Darabi H (2015). Revisiting Warfarin Dosing Using Machine Learning Techniques. Comput Math Methods Med, 2015, 560108.
  25. Biskupiak JE, Biltaji E, Bress A, Unni S, Ye X, Yu B, Mamiya T, Brixner D (2015). Value Assessment for Genetic Testing of Drug Variation In An Elderly Population. Value Health, 18(7), A747.
  26. Drozda K, Wong S, Patel SR, Bress AP, Nutescu EA, Kittles RA, Cavallari LH (2015). Poor warfarin dose prediction with pharmacogenetic algorithms that exclude genotypes important for African Americans. Pharmacogenet Genomics, 25(2), 73-81.
  27. King JB, Bress AP, Reese AD, Munger MA (2015). Neprilysin Inhibition in Heart Failure with Reduced Ejection Fraction: A Clinical Review. Pharmacotherapy, 35(9), 823-37.
  28. McConeghy KW, Bress A, Qato DM, Wing C, Nutescu EA (2014). Evaluation of dabigatran bleeding adverse reaction reports in the FDA adverse event reporting system during the first year of approval. Pharmacotherapy, 34(6), 561-9.
  29. DiDomenico RJ, Bress AP, Na-Thalang K, Tsao YY, Groo VL, Deyo KL, Patel SR, Bishop JR, Bauman JL (2014). Use of a simplified nomogram to individualize digoxin dosing versus standard dosing practices in patients with heart failure. Pharmacotherapy, 34(11), 1121-31.
  30. Bress A, Han J, Patel SR, Desai AA, Mansour I, Groo V, Progar K, Shah E, Stamos TD, Wing C, Garcia JG, Kittles R, Cavallari LH (2013). Association of aldosterone synthase polymorphism (CYP11B2 -344T>C) and genetic ancestry with atrial fibrillation and serum aldosterone in African Americans with heart failure. PLoS One, 8(7), e71268.
  31. Kane SP, Bress AP, Tesoro EP (2013). Characterization of unbound phenytoin concentrations in neurointensive care unit patients using a revised Winter-Tozer equation. Ann Pharmacother, 47(5), 628-36.
  32. Nutescu EA, Drozda K, Bress AP, Galanter WL, Stevenson J, Stamos TD, Desai AA, Duarte JD, Gordeuk V, Peace D, Kadkol SS, Dodge C, Saraf S, Garofalo J, Krishnan JA, Garcia JG, Cavallari LH (2013). Feasibility of implementing a comprehensive warfarin pharmacogenetics service. Pharmacotherapy, 33(11), 1156-64.
  33. Bress A, Patel SR, Perera MA, Campbell RT, Kittles RA, Cavallari LH (2012). Effect of NQO1 and CYP4F2 genotypes on warfarin dose requirements in Hispanic-Americans and African-Americans. Pharmacogenomics, 13(16), 1925-35.
  34. Bress AP, Filtz MR, Truong HA, Nalder M, Vienet M, Boyle C (2011). An Advanced Pharmacy Practice Experience in Melbourne, Australia: Practical Guidance for Global Experiences. Curr Pharm Teach Learn, 1(3), 53-62.
  35. Cavallari LH, Jeong H, Bress A (2011). Role of cytochrome P450 genotype in the steps toward personalized drug therapy. Pharmgenomics Pers Med, 4, 123-36.


  1. Bress AP, Irvin MR, Muntner P (2017). Genetics of Blood Pressure: New Insights Into a Complex Trait. Am J Kidney Dis, 69(6), 723-725.


  1. Bress AP, Tanner RM, Hess R, Gidding SS, Colantonio LD, Shimbo D, Muntner P (2016). Prevalence of Eligibility Criteria for the Systolic Blood Pressure Intervention Trial in US Adults Among Excluded Groups [Abstract]. J Am Soc Hypertens, 10(1), e6-e7.